These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

771 related items for PubMed ID: 11838346

  • 41. Therapeutic consequences of newer studies addressing the problem of myocardial ischemia and ventricular arrhythmias.
    Kuck KH, Siebels J, Schneider MA.
    Herz; 1995 Jun; 20(3):213-8. PubMed ID: 7635402
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Ventricular arrhythmias in heart failure.
    Batsford WP, Mickleborough LL, Elefteriades JA.
    Cardiol Clin; 1995 Feb; 13(1):87-91. PubMed ID: 7796435
    [Abstract] [Full Text] [Related]

  • 48. [Current management of patients with ventricular tachycardia].
    Puljević D, Buljević B, Milicić D.
    Lijec Vjesn; 2001 Feb; 123(7-8):191-200. PubMed ID: 11729615
    [Abstract] [Full Text] [Related]

  • 49. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM, TOVA Investigators.
    Circulation; 2004 Mar 23; 109(11):1386-91. PubMed ID: 14993132
    [Abstract] [Full Text] [Related]

  • 50. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT.
    Grimm W, Alter P, Maisch B.
    Herz; 2004 May 23; 29(3):348-52. PubMed ID: 15167963
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Slade AK, Camm AJ.
    Arch Mal Coeur Vaiss; 1996 Feb 23; 89 Spec No 1():37-49. PubMed ID: 8734163
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Treatment and prevention of sudden cardiac death--what have we learnt from randomised clinical trials?
    Kam RM, Teo WS, Koh TH, Lim YL.
    Singapore Med J; 1999 Nov 23; 40(11):707-10. PubMed ID: 10709412
    [Abstract] [Full Text] [Related]

  • 58. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock.
    Mishkin JD, Saxonhouse SJ, Woo GW, Burkart TA, Miles WM, Conti JB, Schofield RS, Sears SF, Aranda JM.
    J Am Coll Cardiol; 2009 Nov 24; 54(22):1993-2000. PubMed ID: 19926003
    [Abstract] [Full Text] [Related]

  • 59. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.
    Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, Josephson ME, Lehmann MH, Prystowsky EN, MUSTT Investigators.
    J Am Coll Cardiol; 2007 Sep 18; 50(12):1150-7. PubMed ID: 17868806
    [Abstract] [Full Text] [Related]

  • 60. [Treatment of cardiac insufficiency: does treatment depend on whether its cause is ischemic or idiopathic?].
    Galinier M, Bounhoure JP.
    Arch Mal Coeur Vaiss; 1999 Jun 18; 92(6):727-32. PubMed ID: 10410811
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.